|
| |
Monogram BiosciencesMonogram is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable: Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements; and
Pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process
| Contact Details: |
| 345 Oyster Point Blvd. |
| South San Francisco |
| California |
| 94080-1913 |
| United States of America |
| Tel: | (650) 635-1100 |
| Fax: | |
| Email: | |
| WWW: | www.monogrambio.com/
|
|
Loading...
|
Recent Publications by Monogram Biosciences: |  |
EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
HER2 is gene amplified or over-expressed in 20-25% of breast cancers... | 28th October, 2009
| Oncology, Monogram Biosciences, 345 Oyster Point Blvd, South San
| Breast Cancer Res Treat. 2009 Oct 27.
DOI Direct Link |
Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals.
We screened 150 individuals from two recent seroconverter cohorts and... | 21st October, 2009
| Monogram Biosciences, South San Francisco, California 94080, USA.
| AIDS Res Hum Retroviruses. 2009 Aug;25(8):795-802.
DOI Direct Link |
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
The human immunodeficiency virus type 1 (HIV-1) integrase mutations N155H... | 18th September, 2009
| Monogram Biosciences, South San Francisco, CA 94080, USA.
| J Virol. 2009 Nov;83(22):11440-6. Epub 2009 Sep 16.
DOI Direct Link |
Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.
The recent availability of CCR5 antagonists as anti-human immunodeficiency... | 19th August, 2009
| Monogram Biosciences, Clinical Research, South San Francisco, California,
| Antimicrob Agents Chemother. 2009 Nov;53(11):4686-93. Epub 2009 Aug 17.
DOI Direct Link |
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.
We characterized the raltegravir (RAL) susceptibility and the integrase... | 12th August, 2009
| Monogram Biosciences, South San Francisco, California, USA.
| Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4. Epub 2009 Aug 10.
DOI Direct Link |
→View more Monogram Biosciences research publications. |
Press Releases on Monogram Biosciences:
|
 |
| New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance |
12th June, 2009 |
Quest Diagnostics Incorporated |
Faster reporting aids physicians in identifying HIV mutations that can inhibit effectiveness of newest class of antiretroviral therapy
MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest
|
| PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer |
29th April, 2009 |
PDL BioPharma, Inc. |
- Company Updates Board of Directors Audit Committee Members and Complies with Nasdaq Rule -
INCLINE VILLAGE, Nev., April 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today
|
| Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 |
14th April, 2009 |
Washington G-2 Reports |
Washington G-2 Reports releases 2009 Laboratory market projections.
NEWARK, N.J., April 14 /PRNewswire/ -- A new study from market research firm Washington G-2 Reports indicates that the clinical
|
| Monogram Announces 2008 Third Quarter Financial Results |
27th October, 2008 |
Monogram Biosciences, Inc. |
SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the
quarter ended September 30, 2008.
The Company
|
| Monogram Announces a 6-to-1 Reverse Stock Split |
27th October, 2008 |
Monogram Biosciences, Inc. |
SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc., (Nasdaq: MGRM) today announced that its Board of Directors
has approved a 6-to-1 reverse split of its
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 511 times since April 2007, the link to the organisation's website has been followed 57 times Recent Search Terms used to find this page: monogram of the 27th president of the USA | wa company mono gram | monogram homodimerisation | MONOGRAM BIOSCIENCE TROFILES MARKET . pDF | HIV-1 Elite Neutralizers Individuals with Broad and Potent Neutralizing Activity Identified Using a High Throughput Neutralization Assay Together with an Analytical Selection Algorithm | HIV-1 Elite Neutralizers Individuals with Broad and Potent Neutralizing Activity Identified Using a High Throughput Neutralization Assay Together with an Analytical Selection Algorithm | Download monogram of clinical laboratories | monogram patent proximity | . Search for more companies in South San Francisco Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Monogram Biosciences |
